We have recently demonstrated that vorinostat induces synergistic antitumour activity in CRC cell lines in combination with either 5-FU or raltitrexed, a selective quinazoline antifolate TS inhibitor, and sensitises 5-FU-resistant CRC cells to 5-FU. The gene discussed is TYMS; the disease is colorectal carcinoma.